Qiming Corporate GP VI, Ltd. sold $6.0M of ALMR (indirect holdings)
Qiming Corporate GP VI, Ltd. sold 185,731 indirectly-held shares of Alamar Biosciences, Inc. (ALMR) at an average of $32.14 ($30.33–$33.11, $5.97M total) across 20 trades over 2026-10-27 to 2026-10-28. Filed jointly with Qiming Managing Directors Fund VI, L.P. (10% owner), Qiming Venture Partners VI, L.P. (10% owner), Qiming GP VIII, LLC (10% owner), Qiming Venture Partners VIII Investments, LLC (10% owner), Qiming GP VIII-HC, LLC (10% owner) and Qiming Venture Partners VIII-HC, L.P. (10% owner).
How this was made
The 30-second read
Why it matters
The disclosed sale provides fresh data on insider holdings and may affect short‑term price dynamics.
Market read
Primary source filing with modest monetary value; relevance mainly to ALMR traders.
What to watch
No disclosed reason for the sale; could be unrelated to company fundamentals.
Background
Form 4 filing discloses insider transactions required by the SEC.
Ticker impact
Qiming Corporate GP VI, Ltd. sold ~6 M USD of ALMR shares via open‑market transactions on 27‑28 Oct 2026.
likely downward pressure as the market prices the insider sell
The sale represents a material insider transaction for a micro‑cap biotech, suggesting potential concerns.
Market effects
May raise caution for other small‑cap biotech stocks with recent insider sales.
Limited to US biotech sector.
Low
Counterpoint
The sale could be a routine portfolio rebalancing, not a negative signal.
Key entities
- companyAlamar Biosciences, Inc.
US‑listed biotech (ticker ALMR) subject of the insider sale.
- insiderQiming Corporate GP VI, Ltd.
10% owner selling shares.



